Acute Myeloid Leukemia
Conditions
Interventions
Experimental group:Conditioning Regimens:
(1) Busulfan/Cyclophosphamide (Bu/Cy):
Bu: 3.2 mg·kg/1·d 1 × 2 days
Cy: 50 mg·kg/1·d 1 × 2 days
(2) Busulfan/Melphalan (Bu/Mel):
Bu: 3.2 mg·kg/1·d 1 × 2 days
Sponsors
The First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Middle- or high-risk AML patients aged over 60; 2. No suitable allo-HSCT donor or deemed unable to tolerate allo-HSCT; 3. Patients without severe organ damage in the heart, lungs, kidneys, or other functions, with only mild liver impairment (Child grade A); 4. Patients with hepatitis B or C but no active liver injury, who can undergo transplantation if viral replication is strictly monitored and kept below normal copy numbers; those with tuberculosis infection but controlled lesions, who can proceed with transplantation under ongoing anti-tuberculosis treatment; those with recent confirmed fungal infections but fully controlled lesions, who can undergo transplantation under intensified secondary antifungal prophylaxis; 5. Patients who voluntarily sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Age: less than 60 years; 2. Presence of uncontrolled active infections; 3. Impairment of heart, lung, or kidney function and severe liver damage (Child-Pugh Class B-C); 4. Mental illness; 5. Inability to sign an informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Minimal residual disease; | — |
Countries
China
Contacts
Public ContactYuan Hailong
The First Affiliated Hospital of Xinjiang Medical Universit
Outcome results
None listed